Sectors
ASND
Ascendis Pharma A/S
263.04
1 x 264.46
1 x 248.08
bid
ask
+
15.13
6.10%
1 @ 07:30 PM
264.25 +1.21 (0.46%)
| Ytd | 23.35% | |
| 1y | 35.40% |
247.65
day range
268.98
186.05
52 week range
282.15
| Open | 247.65 | Prev Close | 247.91 | Low | 247.65 | High | 268.98 | Mkt Cap | 17.25B |
| Vol | 1.03M | Avg Vol | 648.02K | EPS | 13.04 | P/E | 20.17 | Forward P/E | 27.84 |
| Beta | 0.39 | Short Ratio | 6.97 | Inst. Own | 103.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 254.86 | 200-d Avg | 230.96 | 1yr Est | 315.50 |
| Income Statement | |||
| Total Revenue | 339.29M | ||
| Revenues (USD) | 385.55M | ||
| Cost of Revenue | 27.66M | ||
| Gross Profit | 311.63M | ||
| Operating Expenses | 91.16M | ||
| Research and Development Expense | 75.89M | ||
| Selling, General and Administrative Expense | 173.34M | ||
| Operating Income | 220.47M | ||
| Interest Expense | 14.17M | ||
| Income Tax Expense | 23.12M | ||
| Net Income | 206.97M | ||
| Net Income Common Stock | 206.97M | ||
| Net Income Common Stock (USD) | 235.19M | ||
| Consolidated Income | 206.97M | ||
| Earnings per Basic Share | 3.22 | ||
| Earnings per Basic Share (USD) | 3.66 | ||
| Earnings per Diluted Share | 2.83 | ||
| Earning Before Interest & Taxes (EBIT) | 244.27M | ||
| Earning Before Interest & Taxes (USD) | 277.58M | ||
| Weighted Average Shares | 62.11M | ||
| Balance Sheet | |||
| Cash and Equivalents | 812.26M | ||
| Cash and Equivalents (USD) | 923.02M | ||
| Investments | 30.48M | ||
| Investments Non-Current | 30.48M | ||
| Trade and Non-Trade Receivables | 248.60M | ||
| Current Assets | 1.39B | ||
| Property, Plant & Equipment Net | 135.69M | ||
| Total Assets | 2.29B | ||
| Total Debt | 450.07M | ||
| Current Liabilities | 464.89M | ||
| Debt Non-Current | 450.07M | ||
| Total Liabilities | 849.53M | ||
| Accumulated Retained Earnings (Deficit) | 1.43B | ||
| Shareholders Equity | 1.44B | ||
| Shareholders Equity (USD) | 1.63B | ||
| Assets Non-Current | 895.61M | ||
| Total Debt (USD) | 511.45M | ||
| Deferred Revenue | 2.78M | ||
| Goodwill and Intangible Assets | 3.68M | ||
| Inventory | 310.58M | ||
| Liabilities Non-Current | 384.64M | ||
| Trade and Non-Trade Payables | 103.92M | ||
| Tax Assets | 701.27M | ||
| Tax Liabilities | 12.66M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 4.57M | ||
| Net Cash Flow from Financing | -46.12M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 232.71M | ||
| Capital Expenditure | -3.24M | ||
| Issuance (Purchase) of Equity Shares | -33.09M | ||
| Issuance (Repayment) of Debt Securities | -8.14M | ||
| Net Cash Flow from Investing | -2.85M | ||
| Net Cash Flow from Operations | 281.68M | ||
| Effect of Exchange Rate Changes on Cash | 6.73M | ||
| Share Based Compensation | 29.61M | ||